ClinicalTrials.gg
Not yet recruitingNCT07377799PRIME-LOOPUpdated Feb 2, 2026

Study for the Identification of Subclinical Atrial Fibrillation In Patients With Significant Primary Mitral Regurgitation

An observational study in Mitral Regurgitation and Atrial Fibrillation (AF), sponsored by Rigshospitalet, Denmark. Not yet recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-02.

Sponsored by Rigshospitalet, Denmark · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Mitral Valve Insufficiency with a site in Denmark — 4 open to participants now, 6 under way, none of them phase 3. Mitral Valve Insufficiency · Denmark.

Started
2026
the only one that year
Observational
3 of 13
2 open now
Registered
13th of 13
by date
Lead sponsor
2 of 13
Rigshospitalet, Denmark

Among the 13 studies in Mitral Valve Insufficiency with a site in Denmark, this one is the only one that started in 2026, is one of 3 observational ones, and was the 13th registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

4 of the 13 studies in Mitral Valve Insufficiency with a site in Denmark are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Mitral Valve Insufficiency with a site in Denmark, or all of them as a file.
02

Study summary

The PRIME-LOOP study is a prospective cohort investigating the burden of atrial fibrillation (AF) and subclinical AF in patients with moderate-severe or severe primary mitral regurgitation (MR). The study will use long-term cardiac monitoring with an implantable loop recorder (ILR) for up to three years to identify the burden of AF. Further, the study aims to examine the associated risk of adverse events among patients with detected AF as compared with patients without AF. Only patients with no or mild symptoms related to MR and without a class I indication for surgical intervention will be included. The study aims to include 100 patients.

Patients will be screened from the PRIME cohort - a prospective cohort of patients with primary MR in East Denmark.

Read the detailed description

Purpose

There are two main purposes of this study: 1) to assess atrial fibrillation (AF) burden in patients with asymptomatic severe primary degenerative mitral regurgitation (MR) but no known AF using the CE marked Reveal LINQ™ Insertable Cardiac Monitor (ICM), and 2) to examine the association between subclinical AF and deterioration of left ventricular (LV) dysfunction, progression of symptoms, and time to surgery.

We hypothesize that:

  1. Within one year of follow-up, up to 30% of patients with significant, asymptomatic, primary MR will have previously unknown AF detected when evaluated by continuous monitoring.
  2. The deterioration of LV dysfunction, progression of symptoms, and time to surgery are aggravated by subclinical AF.

Background

Mitral regurgitation and atrial fibrillation MR is the second most common reason for heart valve surgery in the Western World and the most common valvular heart disease. For patients with severe primary MR the only curative approach is an invasive assessment, usually with mitral valve surgery. There exist clear guidelines for the assessment of patients with symptomatic severe primary MR and with a class I recommendation, surgery is recommended, level of evidence B. The evidence supporting this recommendation is based on observational data. However, timing of surgery is much debated, and no randomized controlled trials have been conducted, for the assessment of patients with asymptomatic severe primary MR. It has been of interest to identify factors associated with worse outcomes in this patient population in order to guide clinical decision of early surgery. AF is a common complication in patients with severe primary MR. Increased left atrial pressure from primary MR leading to left atrial enlargement and remodeling is hypothesized to be the pathophysiologic driver for the development of AF. From non-continuous electrocardiography (ECG) monitored patients, the incidence rate of AF has been around 20% within a 5 year period, however this study was conducted between 1989 and 1994 where monitoring devices were not as extensively used as in contemporary health care systems in the Western world.7 Another study identified AF among 32% of patients at the time of the primary MR diagnosis.8 Several observational studies have linked AF with worse outcomes, as compared with patients without AF - regardless of surgery. These observational findings have led to the guideline recommendation that patients with asymptomatic severe primary MR and AF should be considered for surgery (class IIa recommendation, level of evidence B). Studies investigating the interplay between AF and primary MR have primarily been limited by the absence of a clearly defined protocol for the detection of AF. Most commonly, AF was identified with an electrocardiogram taken concomitantly with the diagnostic echocardiography or at the discretion of the clinician following primary MR diagnosis. Compared with external loop recording, where patients are monitored continuously for 30 days, long-term continuous monitoring using an implantable loop recorder (ILR) has an up to three times higher rate for the detection of AF within one year in patients with ischemic stroke. Continuous heart rhythm monitoring and the detection of subclinical AF is being used more and more common, however which clinical consequences to draw from this finding is unknown in patients with severe MR. In cases of severe asymptomatic primary MR, where the identification of AF could influence the decision for surgery, employing a systematic and ongoing screening approach may aid in determining, whether AF is a factor associated with adverse outcomes. Additionally, this approach would provide insights into establishing the optimal time threshold for associating AF with worse outcomes.

Implantable loop recorder The Reveal LINQ insertable cardiac monitor or implantable loop recorder is a widely used device for detecting cardiac arrhythmias including AF. The insertion procedure is minimally invasive and requires little time and clinical resources. The device is placed under the skin of the chest and automatically records and remotely transmits arrhythmia episodes along with daily summary-level heart rhythm data to the clinician. Thresholds for arrhythmia annotation can be adjusted to accommodate the individual setting but have generally proven to have a very high sensitivity and high specificity for AF. Symptom-prompted ECG recordings can be transmitted by the use of a hand-held "symptom button" (Patient Assistant, PA96000) that comes with the device.15, 16 Additional remote transmissions to save all ECG material can be performed by the patient. The device has a battery-life of at least 3 years.

Methods

Design The study is designed as a case study with follow-up, involving 100 participants with asymptomatic or mildly symptomatic, moderate-severe or severe primary MR where surgical intervention is not planned. Participants will be screened for inclusion (see chapter 8) and upon study eligibility and consent from the participant, an ILR will be implanted. Participants will be screened from an already established prospective cohort of patients with primary MR (The PRIME cohort, p-2025-18689). Patients included in this cohort have already consented to be contacted for enrolment in studies related to primary MR. Hence, inclusion will not rely on screening in the clinic.

From the day of implantation, the burden of AF will be remotely monitored. When data on AF burden has been collected, the impact of AF burden on clinical outcomes will be examined.

Trial specific treatment/evaluations Participating in this trial, requires the participantto meet at Rigshospitalet for a total of three site visits: at baseline, after 12 months and after 36 months. On the first visit, the participant will have the ILR implanted, participate in a medical interview, undergo echocardiography, blood tests, and the HeartQol questionnaire. The second visit will only include echocardiography, blood tests, and the HeartQol questionnaire, while the final visit will also include ILR explantation. The dates of visit will, if possible, be coordinated with the participant'sstandard consultation for primary MR, to minimize unnecessary time and travel costs for the participants.

Procedures upon detection of clinically relevant arrythmias During the three-year heart rhythm monitoring, potential arrythmias may be detected. If an arrhythmia is detected by the ILR, the coordinating investigator or a delegate will review the recorded rhythm via the CareLink® Remote Monitoring Network within one week of the alarm. Upon diagnostic uncertainty, data will be further reviewed by a senior cardiologist with expertise in arrythmia. If there is discrepancy in the assessment of the rhythm recorded by the ILR, a third senior cardiologist will independently evaluate the rhythm where at least two cardiologists are needed to confirm the diagnosis. All event data will be continuously logged in RedCap.

The following findings from the ILR will lead to participant contact and consideration of alterations in medical treatment:

  1. A new AF episode ≥24 hours and a CHADS-VA score >1 will lead to participant contact and recommendation of oral anticoagulant treatment taking bleeding risk into account.

    Rate control will be considered with beta blocker, digoxin, or non-dihydropyridine calcium antagonist. Follow-up will be ensured to be at the general physician or the local department of cardiology.

  2. Clinically significant bradyarrhythmia (i.e., 2nd degree atrioventricular block type 2 and complete heart block with ≥4 beats at rate \<30 beats/min, sinus arrest/asystole >3 seconds) will lead to participant contact to identify symptoms such as syncope, shortness of breath, dizziness. A senior colleague and/or senior consultant, with specialty within cardiac pacemakers will be consulted for consideration of permanent pacemaker implantation.
  3. Ventricular tachycardia (VT). The participant will be contacted in case of non-sustained or sustained VT to identify symptoms such as palpitations, chest pain, syncope, dizziness. In case of sustained VT, the participant will be admitted to the local cardiology award for consideration of an Implantable electronic device. In case of non-sustained VT referral to the local department of cardiology will be considered for non-invasive test for myocardial ischemia and consideration of initiation of beta blocker.

Alterations in medical treatment are warranted when one of the abovementioned findings may be identified to reduce the risk of ischemic stroke, heart failure, syncope, myocardial ischemia, cardiac arrest and can be prevented if timely and correct medical therapy is initiated.

The coordinating investigators will review alerts from the ILR and upon detection of one the abovementioned findings, alterations in medical management will be discussed with the principle investigator and the expert committee. The final decision as to whether trial participant will be informed of a secondary finding shall be made by the principal investigator, based on a clinical and ethical assessment and in accordance with applicable ethical guidelines and recommendations from the relevant ethics committee.

Procedures upon detection of other significant clinical findings Through blood tests and echocardiography, study personnel may identify previously undiagnosed conditions requiring further monitoring, diagnostic evaluation, or treatment initiation. If such findings occur, the participant will be informed and advised to contact their attending physician. As with arrhythmia detection, any subsequent interventions will be at the discretion of the partipant's attending physician.

Outcomes

The outcomes are examined during the three years from ILR implantation to ILR explantation. In addition, follow-up studies will be conducted at 5 and 10 years after explantation to further investigate the association between subclinical AF and adverse outcomes assessed from medical records. All outcomes are listed below.

Primary outcome Atrial fibrillation detection: Episode of ≥6 minutes of consecutive AF at any time during the 3-year monitoring time

Statistical considerations and data analyses

Statistical considerations The study is explorative in character, as the burden of AF in this population has not been examined with continuous monitoring previously. The expected proportion of participants that will be identified with AF, and the potential association with adverse outcomes, is based on pathophysiological theory and previous observational studies. In the LOOP-study, an ILR was assigned to 1,501 participants with no history of AF (median age 75 years) and at least one stroke risk factor (i.e., hypertension, diabetes, previous stroke, or heart failure).20 Among these, the authors found AF with a ≥6 min duration among 21% within 12 months and 31.8% within a median follow-up time of 39 months. With the considerable risk of AF linked to the presence of severe MR, we find it plausible that a similar or even higher rate of AF may be detected, as compared with that of the LOOP-study. Thus, we expect that this study will identify AF in up to 30% of the included participants within 12 months and 50% within 36 months. This rate is further supported by older studies that have identified AF in 20-30% of non-continuously monitored patients at the time of MR diagnosis. A key parameter in the clinical decision for surgical intervention is left ventricular end systolic diameter (LVESD). Patients with LVESD ≥40 mm have been associated with high mortality,21 hence LVESD ≥40 mm has become a class I indication for surgical intervention.2 We estimate that participants without AF detected by the ILR will have a mean LVESD of 35 mm with a standard deviation of 8 mm as measured by echocardiography at end of follow-up. For participants with AF as detected by ILR, the mean LVESD will be estimated at 40 mm. Assuming a two-sided alpha of 0.05 and a statistical power of 80% to detect this 5 mm increment in LVESD, a sample size of 40 participants per group is required for the study. Encountering dropouts and insecurity in estimates, we aim to enroll a total of 100 participants in total where it is estimated that around 50% will be categorized in the AF group and 50% will be categorized in the no AF group.

Data analyses This study will include 100 participants, all with an ILR. Should any dropouts occur, they will be replenished with new participants until the predetermined sample size is attained.

Secondary per-protocol analyses will be conducted, including only participants who complete the planned follow-up without major protocol deviations. The main analyses will be performed using multivariable Cox regression, assessing both the presence of AF as a baseline exposure and the occurrence of AF as a time-dependent covariate.

Participants who become pregnant during the study will be excluded from further monitoring from the date of pregnancy detection and censored at that time in the per-protocol analysis. Missing data will be handled using appropriate statistical methods depending on the extent and pattern of missingness (e.g., multiple imputation if data are missing at random).

Study participants

Eligible participants Participants eligible for inclusion are participants who are potential candidates for mitral valve surgery but do not meet the criteria for class I intervention and have not been diagnosed with AF, see below.

Inclusion criteria Asymptomatic/mildly symptomatic*, significant primary MR** LVEF ≥60% Native mitral valve Age ≥18 years old

Exclusion criteria Planned for mitral valve surgery LVESD ≥ 40 mm Prescence of cardiac pacemaker, ICD, cardiac resynchronization device, loop recorder, or a clinical indication for loop recorder Life expectancy \< 1 year Pregnancy or lactating Prior diagnosis of AF

* Asymptomatic is defined as not being restricted in everyday activities due to dyspnea and have the functional capacity of walking to the second floor without being dyspneic (METS≥4). The evaluation of symptoms will be on the discretion of the treating physician.

**MR may be defined by either of two:

  1. EROA ≥30 mm2 or regurgitation volume ≥45 mL.
  2. If two cardiologists specialized in valvular heart assessment both consider the regurgitation to be moderate-severe or severe.

Abbreviations: MR: mitral regurgitation; AF: atrial fibrillation; ICD: implantable cardioverter defibrillator; LVESD: left ventricular end-systolic diameter; LVEF: left ventricular ejection fraction.

Discontinuation Participants reserve the right to terminate their involvement in the trial at any time. For participants who may become pregnant or is planned for cardiac valve surgery during the study period, the participant is informed to contact the coordinating investigator to have the ILR explanted. Likewise, investigators retain the authority to cease a participant's engagement if medical circumstances arise that preclude continued participation. In the event of discontinuation, all data pertaining to the participant will be retained up to the point of their withdrawal from the trial.

03

Conditions studied

  • Mitral Regurgitation
  • Atrial Fibrillation (AF)

Keywords

  • degenerative mitral regurgitation
  • asymptomatic
  • atrial fibrillation
  • subclinical atrial fibrillation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with moderat-severe or severe primary mitral regurgitation with no or mild symptoms without a class I indication for surgical intervention

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Asymptomatic/mildly symptomatic*, significant primary MR**
  • ≥60%
  • Native mitral valve
  • Age ≥18 years old

Exclusion criteria

Exclusion Criteria:

  • Prior diagnosis of AF
  • Prescence of cardiac pacemaker, ICD, cardiac resynchronization device, loop recorder, or a clinical indication for loop recorder
  • LVESD ≥ 40 mm
  • Planned for mitral valve surgery
  • \< 1 year
  • Pregnancy or lactating
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with ILR
06

What researchers measure

Primary outcomes

  1. Atrial fibrillation detection

    Episode of ≥6 minutes of consecutive AF at any time during the 3-year monitoring time

    Time frame: 3 years

Secondary outcomes

  1. Atrial fibrillation detection

    Episode of ≥2 minutes of consecutive AF

    Time frame: 3 years

  2. Supraventricular tachycardia

    Rate \>150 bpm lasting ≥16 beats

    Time frame: 3 years

  3. Sinus arrest/asystole

    Pauses \> 3 seconds

    Time frame: 3 years

  4. Atrioventricular block

    Second-degree or complete block with ≥4 beats at a rate \<30 bpm

    Time frame: 3 years

  5. Sustained ventricular tachycardia

    Rate \>150 bpm lasting ≥30 seconds

    Time frame: 3 years

  6. Nonsustained ventricular tachycardia

    Rate \>150 bpm lasting \<30 seconds

    Time frame: 3 years

  7. Ventricular fibrillation

    Any duration

    Time frame: 3 years

  8. AF burden

    Percentage of monitored time spent in AF rhythm, categorized as: 1) \<0.05%, 2) 0.05% to 0.5%, 3) 0.5% to 5%, and 4) \>5%

    Time frame: 3 years

  9. AF progression

    Increase in burden in the second half of follow-up compared to the first half

    Time frame: 3 years

  10. Increase in NT-proBNP

    Percentage increase in NT-proBNP between the first and last recorded value

    Time frame: 3 years

  11. Increase in left ventricular end-systolic diameter (LVESD)

    Percentage increase in LVESD between the first and last echocardiography

    Time frame: 3 years

  12. Increase in pulmonary artery systolic pressure (PASP)

    Percentage increase in PASP between the first and last echocardiography

    Time frame: 3 years

  13. Left atrial (LA) enlargement

    LA size of \>60 mL

    Time frame: 3 years

  14. Development of clinically diagnosed AF

    Symptomatic AF diagnosed at an in- or out-patient contact with a 12-lead electrocardiogram with AF in its entire length or long-term heart rhythm monitoring with ≥30 sec of AF

    Time frame: 3 years

  15. Diagnosis of HF

    HF diagnosed in an out-patient clinic or hospitalization for HF (criteria: HF as a primary diagnosis, admission ≥24 hours, presenting with symptoms and objectives signs and laboratory findings of HF and receiving HF treatment)

    Time frame: 3 years

  16. Change in symptoms and quality of life

    Measured by changes in participant-reported HeartQol questionnaire. Minimum score 0 and maximum score 42 where a higher score indicates a better health status

    Time frame: 3 years

  17. Initiation, discontinuation, or adjustment of antiarrhythmic medications

    Recorded from electronic medical records

    Time frame: 3 years

  18. Initiation of anticoagulation therapy

    Recorded from electronic medical records

    Time frame: 3 years

  19. Referral to or performance of cardiac surgery

    Recorded from electronic medical records

    Time frame: 3 years

  20. Hospitalization ≥24 hours (all-cause and cardiovascular-specific)

    Recorded via electronic medical records Cardiovascular hospitalization: Hospitalization due to structural heart disease, worsening or de novo heart failure, arrhythmia, ischemic heart disease, venous thromboembolism, stroke.

    Time frame: 3 years

  21. Stroke or systemic embolism

    Recorded via electronic medical records Criteria stroke: diagnosed in an in- or outpatient setting with new-onset focal or global neurological dysfunction lasting ≥24 hours, preferably confirmed by imaging or combined with initiation of anticoagulation therapy Criteria systemic embolism: clinical history consistent with an acute loss of blood flow in a peripheral artery with evidence of embolism (identified surgically, by autopsy or imaging)

    Time frame: 3 years

  22. Cardiovascular and all-cause mortality

    Recorded via electronic medical records Cardiovascular (CV) death includes any death resulting from an acute myocardial infarction, sudden cardiac death, sudden death, death due to HF, death due to stroke, death due to CV procedures, death due to CV hemorrhage, and death due to other CV causes

    Time frame: 3 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Feb 2028, 24 months later.

Of 73 non-industry observational studies under Mitral Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 192. This study's planned 24 months is below that.

Counting every sponsor, half of 85 studies reached it within 57 months; a quarter within 26 and three quarters within 192.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2026
First posted
Jan 30, 2026
StartEst.
Feb 1, 2026
Primary completionEst.
Feb 1, 2028
CompletionEst.
Feb 1, 2031
Last update
Feb 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07377799
Responsible party
Lauge Østergaard (PRospective cohort study for the Identification of Subclinical atrial fibrillation In patients with significant primary Mitral valve regurgitation, Rigshospitalet, Denmark) — Principal investigator
First posted
Jan 30, 2026
Start date
Feb 1, 2026 (estimated)
Primary completion
Feb 1, 2028 (estimated)
Completion
Feb 1, 2031 (estimated)
Last update
Feb 2, 2026

Study contacts

Lauge Klement Moltke Østergaard, MD PhD
Contact
lauge.klement.moltke.oestergaard.02@regionh.dk
0045 35454295
Jeppe Petersen, MD
Contact
jeppe.kjaergaard.petersen@regionh.dk

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion